SCTx

SCTx is a biotechnology company focused on developing next-generation hematopoietic stem cell (HSC) therapies for the treatment of hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Co-founded by renowned oncologist Siddhartha Mukherjee, the company utilizes advanced gene-editing technologies, such as CRISPR, to engineer shielded stem cells that are resistant to targeted cancer therapies. This approach allows for the aggressive targeting of cancer cells while preserving the patient's healthy immune system and bone marrow function. SCTx aims to overcome the limitations of current cell therapies by creating a more durable and less toxic treatment paradigm for blood cancers.